在中空纤维膜装备制造领域，技术创新是企业立足市场的核心。上海湛信科技发展有限公司（旗下品 牌"上海鑫高度"）凭借"多孔中空纤维膜喷丝装置"（授权公告号：CN106435788B）及"插入管式多孔喷 丝头"（授权公告号：CN116356437B）两项专利，持续领跑行业技术前沿。 专利技术：结构创新破解行业痛点 "多孔中空纤维膜喷丝装置"专利以"多孔组合式"结构为核心，由进料板、芯液导流板、喷丝板及独立喷 丝头构成。进料板与芯液导流板上下衔接，喷丝板固定于芯液导流板下端，多个独立喷丝头通过可拆卸 设计嵌入喷丝板组装孔，既突破了传统单孔喷丝头"一次出一根丝"的低效瓶颈，又解决了早期多孔设备 料液、芯液流动不均的问题。 装置的"均匀性设计"是关键突破。喷丝板内的料液腔与芯液导流板的芯液腔通过均流环结构，确保料 液、芯液在同等压力下同步进入各独立喷丝头。料液需先填满料液腔，待液位超过均流环高度后才流入 喷丝头；芯液则通过对称分布的分流孔实现均匀分配，使膜丝厚度偏差控制在0.003mm内，一致性较传 统设备提升80%以上。 技术迭代：打造综合技术解决方案提供商 两项专利是上海鑫高度技术迭代的重要成果。其中"多孔中空纤维膜 ...

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].